AngioDynamics announced that its Relief feasibility study, evaluating the Nanoknife irreversible electroporation (IRE) platform as a minimally invasive treatment for benign prostatic hyperplasia (BPH), has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). – Bitget
AngioDynamics公司宣布，其用于评估Nanoknife不可逆电穿孔（IRE）平台作为良性前列腺增生（BPH）微创治疗方案的Relief可行性研究，已获得美国食品药品监督管理局（FDA）的研究用器械豁免（IDE）批准 Bitget
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Frequently Asked Questions
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
